A new clinical guideline on hepatitis B virus (HBV) urges physicians to vaccinate all unvaccinated adults who are at risk for infection, including pregnant women, and routinely screen at-risk adults.

AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the ...

Chronic hepatitis B (CHB) remains a major global challenge. Current therapies suppress HBV but rarely achieve functional cure ...

The American Academy of Pediatrics recommends that all infants receive the hepatitis B vaccine at birth, with follow-up doses at 1 to 2 months and 6 to 18 months. Adults younger than 60 who haven't ...

Coexisting MASLD in patients with chronic HBV is associated with a lower risk for severe liver disease but a higher coronary heart disease risk.

In 2016, all WHO Member States committed to eliminating viral hepatitis as a public health threat by 2030.1 The principal ...

Tenofovir alafenamide fumarate achieves viral suppression rates comparable to tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection, with an improved safety profile, ...

Please provide your email address to receive an email when new articles are posted on . Global HBV incidence and mortality rates dropped from 1990 to 2021 among individuals aged 15 to 49 years.

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

Hepatitis B virus (HBV) has a narrow host range, mainly infecting hominoids. A new study reveals the structural differences in the liver cell receptor (NTCP) between humans and monkeys, explaining why ...